Promising initial efficacy data with 60% volumetric response rate across doses and 29%* at the lowest tested dose of 100mg twice daily (BID) with all patients ongoing Interim investigator- and patient ...
Promising initial efficacy data with 60% volumetric response rate across doses and 29%* at the lowest tested dose of 100mg twice daily (BID) with all patients ongoing. Interim inv ...
Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), will present new data from nine approved and investigational medicines across more than 15 indications at the 2026 American Society ...
FDA Breakthrough Therapy designation granted to zovegalisib for PIK3CA-mutant, HR+/HER2- advanced breast cancer, the Phase 3 ReDiscover-2 trial ...
Triplet gedatolisib/fulvestrant/palbociclib achieved the primary endpoint, significantly improving PFS versus alpelisib/fulvestrant in PIK3CA-mutant HR+/HER2− ...
Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline developmentCompelling efficacy and tolerability data for zovegalisib ...
Accurate detection of PIK3CA mutations is essential for personalizing breast cancer treatment, particularly with PI3K-targeted therapies. However, conventional molecular testing is not always ...
After a Consumer Reports investigation revealed that some popular protein powders and shakes contained troubling levels of lead, many readers wrote in with a simple question: What does this mean for ...
Additional analysis of data from a Phase 1b clinical trial that included all patients treated with gedatolisib combined with fulvestrant and palbociclib showed median progression-free survival (“PFS”) ...
From drinks to meals to weight loss tonics, it seems the internet is always serving up another recipe to boost your health. The latest trend? Coffee plus protein, or “proffee,” as it’s sometimes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results